Synaffix BV

Synaffix BV today announces it has entered into a licensing agreement with Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The agreement allows Elevation access to Synaffix's clinical stage, site-specific #ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, as well as the toxSYN® linker-payload, SYNstatin E™, for the development of its new HER3 ADC program, EO-1022. Synaffix is eligible to receive up to $368 million in upfront and clinical, regulatory and commercial milestone payments, plus tiered royalties on net sales. For more information, see the full press release linked in the comments below. #ADCs #oncology #drugdevelopment #biotech

Synaffix BV today announces it has entered into a licensing agreement with Illumina, a global leader in DNA sequencing and array-based technologies.   The agreement grants #Illumina access to Synaffix's patented metal-free click chemistry, for next-generation DNA sequencing applications.   For more information, please see the full press release linked in the comments below.   #drugdevelopment #NGS #metalfreeclickchemistry #DNA

Synaffix BV today announces it has licensed its #ADC technology to BigHat Biosciences.   BigHat will combine Synaffix technology with its world-class machine learning #antibody design platform for the development of a new ADC pipeline program.     Under the terms of the agreement, BigHat will receive target-specific access to Synaffix’s late-clinical stage, site-specific ADC technology platform, which enables the transformation of antibodies into proprietary, best-in-class ADC products. BigHat will also gain access to Lonza’s end-to-end ADC offering. For more information on this exciting new collaboration, please read the full press release linked in the comments below. #ADCs #drugdevelopment #innovation #artificialintelligence #machinelearning

The Synaffix BV team will be in San Diego next week for #WorldADC 2024. Anette Sommer will give a presentation on how Synaffix's Platform Technologies enable #ADCs with best-in-class therapeutic index potential. The presentation will also detail the rapidly advancing pipeline of GlycoConnect® ADCs and the clinical developments of the most advanced assets. If you are attending, make sure to say hello to find out more about how Synaffix’s best-in-class #ADCplatform can revolutionise your pipeline. World ADC Event Series

After establishing the early programs within Synaffix BV, we spun out Kivu Bioscience, just prior to being acquired by Lonza, in June 2023. Kivu is utilizing the Synaffix proprietary site-specific conjugation and linker-payload technologies, which enhance the stability and efficacy of #ADCs while significantly minimizing off-target side effects. We congratulate Mohit Trikha, the Kivu Team, Daniel O'Connell MD,PhD and all investors of the Series A led by Novo Holdings on the successful financing and emerging from ‘stealth mode’. We look forward to supporting them as they advance their pipeline of promising #ADC #medicines for patients in areas of high unmet medical need. https://lnkd.in/eHudVNKA

Not only is our industry-leading technology able to significantly level up your ADC pipeline, we can also transform your bispecific offering! We are able to directly convert any off-the-shelf antibody into a bispecific. Our technology enables immune cell engagers and other protein conjugates, differentiated through our novel 2:1 format which is expected to deliver a safety advantage, and avoids co-expressing a genetic fusion of two separate antibodies/binding domains. Visit our website linked below to learn more. #drugdevelopment #ADCs #biotech

Our toxSYN™ technology consists of a number of linker-payloads. We provide multiple options to maximize efficacy in light of tumor biology. Choose one of our linker-payloads, attach to your antibody under a technology evaluation and go straight into #ADC product development following positive proof-of-concept. Synaffix BV enables best-in-class ADCs, all under one roof. Get in touch visit our website in the comments below to learn more. #drugdiscovery #biotech #ADCs

We are excited about the innovative work Dr. Annemieke Aartsma-Rus and her team at Leiden University using GlycoConnect™. Thank you to Dr. Aartsma-Rus for the continued collaboration.  #ADCs #innovation #antibodies #Synaffix #Lonza

HydraSpace™, a compact and highly polar spacer technology. HydraSpace™ enables efficient attachment of the most challenging hydrophobic payloads to an antibody, and with its branching capability two distinct payload types can be attached to the same antibody – a dual-warheaded ADC format– a key strategy in the eradication of cancer stem cells and the treatment of multi drug resistant forms of cancer. Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves therapeutic efficacy, tolerability, pharmacokinetics, and manufacturability. Visit our website linked below to learn more about HydraSpace™. #drugdevelopment #ADCs #biotech